spacer
home > ict > autumn 2008 > more than a lifestyle drug
PUBLICATIONS
International Clinical Trials

More than a Lifestyle Drug

Urological diseases or dysfunctions will afflict most of us at some point in our adult lives and will have a severe negative impact on quality of life. Urological conditions range from common ‘bothersome’ complaints such as urinary incontinence, benign prostatic hyperplasia (BPH) and male sexual dysfunction, profoundly uncomfortable and painful conditions such as kidney stones and interstitial cystitis, and life-threatening prostate, bladder and kidney cancers.

The underlying aetiology of certain urological diseases is well understood and has resulted in the introduction of several ‘blockbuster’ drugs during the last decade designed for the treatment of overactive bladder (OAB), BPH and erectile dysfunction. Few effective pharmaceutical remedies are available for more complex urological conditions such as stress urinary incontinence, premature ejaculation, chronic prostatitis and interstitial cystitis.

Current urological drug development is attempting to address these significant unmet or poorly met medical needs, and to bring more effective and better tolerated...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Wyllie has over 25 years of experience in senior management level positions within the pharmaceutical industry. He started out as Director of Biology at Pfizer from 1984-1998. Subsequently, he established Urodoc Ltd, a strategic planning and medical education company servicing the pharmaceutical industry. In 2003, he co-founded Plethora Solutions Ltd, a company specialising in IP generation, urological and andrological drug development and Phase II clinical trials. He is also a non-executive Director and CSO of the medical technology company Zi Medical Plc. In 2006 Mike became founding partner of Global Pharma Consulting Ltd, which provides interim management support across a wide range of functions to medium and small biopharmaceutical and medical technology companies. In December 2006 he helped to float the Chinese pharmaceutical company Taihua (AIM:TAIH) and joined the boards of Bactomed Ltd and Bluescope Ltd. Mike is named inventor on over 100 methods of treatment, formulation and device patents.
spacer
Mike Wyllie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; safety and additional efficacy data continue to be collected Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints
More info >>

White Papers

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal

ArisGlobal LLC Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement